Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results

Table 2 Comparison of the baseline characteristics of patients on simeprevir- and/or sofosbuvir-based regimens and patients on telaprevir- or boceprevir-based regimens

	SMV- and/or SOF-containing regimens	TVR- or BOC-containing regimens	P-value
	Continuous: median (IQR)/categorical: n (%)
n	508	223
Age, yr	60 (54-64)	57 (51-61)	< 0.011
Race, black, n (%)	71/508 (14)	41/223 (18)	0.132
Gender, female, n (%)	183/508 (37)	79/223 (35)	0.892
BMI, kg/m2>	27.7 (24.7-30.8)	27.1 (24.5-30.7)	0.651
Diabetes, n (%)	111/508 (22)	48/223 (22)	0.892
Naïve to treatment, n (%)	204/508 (40)	68/223 (31)	0.012
HCV viral load, log IU/mL	6.15 (5.61-6.58)	6.31 (5.89-6.66)	< 0.013
Hemoglobin, g/dL	13.8 (12.6-15.1)	14.3 (13.1-15.3)	< 0.011
Platelet, × 103/μL	143 (90-195)	152 (107-195)	0.193
ALT, U/L	63 (39-105)	67 (44-106)	0.133
AST, U/L	62 (38-99)	62 (39-104)	0.753
Albumin, g/dL	4.0 (3.5-4.4)	4.2 (3.9-45)	< 0.011
FIB-4 score	3.54 (1.73-6.72)	2.65 (1.77-5.60)	0.063
FIB-4 ≥ 3.25, n (%)	267/508 (54)	98/221 (44)	0.032

¹T-test;

²χ²;

³Mann-Whitney. SMV: Simeprevir; SOF: Sofosbuvir; TVR: Telaprevir; BOC: Boceprevir; IQR: Interquartile range; BMI: Body mass index; HCV: Hepatitis C virus; ALT: Alanine transaminase; AST: Aspartate transaminase.